Ted Drogendijk

2.1k total citations · 1 hit paper
22 papers, 1.6k citations indexed

About

Ted Drogendijk is a scholar working on Urology, Epidemiology and Rheumatology. According to data from OpenAlex, Ted Drogendijk has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Urology, 13 papers in Epidemiology and 13 papers in Rheumatology. Recurrent topics in Ted Drogendijk's work include Urinary Bladder and Prostate Research (17 papers), Urinary Tract Infections Management (13 papers) and Pelvic floor disorders treatments (13 papers). Ted Drogendijk is often cited by papers focused on Urinary Bladder and Prostate Research (17 papers), Urinary Tract Infections Management (13 papers) and Pelvic floor disorders treatments (13 papers). Ted Drogendijk collaborates with scholars based in Netherlands, United Kingdom and Japan. Ted Drogendijk's co-authors include Christopher R. Chapple, John Bolodeoku, Arwin Ridder, Peter J. Boerrigter, L. Cardozo, Nancy Martin, Jiří Klečka, Igor V. Kuzmin, R. J. Millard and Caroline A. Dorrepaal and has published in prestigious journals such as The Journal of Urology, European Urology and European Journal of Cancer.

In The Last Decade

Ted Drogendijk

22 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

2012 329 citations Vik Khullar, G. Amarenco et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ted Drogendijk Netherlands	13	1.4k	1.2k	916	165	136	22	1.6k
Mary Beth Blauwet United States	14	509 0.4×	415 0.4×	317 0.3×	109 0.7×	68 0.5×	31	933
M. Oelke Germany	14	2.1k 1.4×	1.1k 1.0×	306 0.3×	202 1.2×	1.3k 9.5×	32	2.3k
Weizhong He United States	11	391 0.3×	298 0.3×	137 0.1×	104 0.6×	235 1.7×	25	721
M. C. DELAUCHE‐CAVALLIER France	9	477 0.3×	139 0.1×	67 0.1×	158 1.0×	192 1.4×	10	694
K‐E. Andersson Sweden	8	208 0.1×	104 0.1×	69 0.1×	40 0.2×	64 0.5×	10	444
Hüseyin Beşiroğlu Türkiye	16	186 0.1×	100 0.1×	76 0.1×	115 0.7×	218 1.6×	61	734
Shyh-Chyan Chen Taiwan	16	160 0.1×	56 0.0×	42 0.0×	203 1.2×	96 0.7×	33	512
J.M. Gaya Spain	13	77 0.1×	32 0.0×	149 0.2×	264 1.6×	188 1.4×	45	648
Hiroki Okada Japan	11	120 0.1×	65 0.1×	42 0.0×	81 0.5×	62 0.5×	36	417
Takeshi Imaoka Japan	19	106 0.1×	36 0.0×	77 0.1×	249 1.5×	76 0.6×	50	1.2k

Countries citing papers authored by Ted Drogendijk

Since Specialization

Citations

This map shows the geographic impact of Ted Drogendijk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ted Drogendijk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ted Drogendijk more than expected).

Fields of papers citing papers by Ted Drogendijk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ted Drogendijk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ted Drogendijk. The network helps show where Ted Drogendijk may publish in the future.

Co-authorship network of co-authors of Ted Drogendijk

This figure shows the co-authorship network connecting the top 25 collaborators of Ted Drogendijk. A scholar is included among the top collaborators of Ted Drogendijk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ted Drogendijk. Ted Drogendijk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mathias, Susan D., Ross D. Crosby, Jameel Nazir, et al.. (2014). Validation of the Patient Perception of Intensity of Urgency Scale in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. Value in Health. 17(8). 823–829. 10 indexed citations

Drake, Marcus J., Christopher R. Chapple, Matthias Oelke, et al.. (2014). Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension. European Urology. 67(2). 262–270. 48 indexed citations

Mathias, Susan D., Ross D. Crosby, Monique Klaver, et al.. (2013). The patient perception of intensity of urgency scale (PPIUS): Its validation in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Value in Health. 16(3). A37–A37. 1 indexed citations

Kerrebroeck, Philip Van, Christopher R. Chapple, Ted Drogendijk, et al.. (2013). Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial. European Urology. 64(6). 1003–1012. 69 indexed citations

Chapple, Christopher R., Vladimír Dvořák, Philip Van Kerrebroeck, et al.. (2013). A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal. 24(9). 1447–1458. 107 indexed citations

Cardozo, Linda, et al.. (2013). Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin ( SUNRISE ). British Journal of Urology. 111(5). 804–810. 26 indexed citations

Chapple, Christopher R., Marcus J. Drake, Philip Van Kerrebroeck, et al.. (2013). Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. British Journal of Urology. 113(5). 696–703. 29 indexed citations

Drake, Marcus J., Monique Klaver, Ted Drogendijk, et al.. (2013). 1089 Quality of life analyses from NEPTUNE, a phase 3 trial of combination therapy with tamsulosin OCAS™ and solifenacin in men with lower urinary tract symptoms. European Urology Supplements. 12(1). e1089–e1090. 3 indexed citations

Chapple, Christopher R., Steven A. Kaplan, David Mitcheson, et al.. (2012). Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder. European Urology. 63(2). 296–305. 243 indexed citations

10.

Khullar, Vik, G. Amarenco, J.C. Angulo, et al.. (2012). Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial. European Urology. 63(2). 283–295. 329 indexed citations breakdown →

11.

Lee, Jennifer, Marloes Schaddelee, Wenhui Zhang, et al.. (2012). Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder. International Journal of Clinical Pharmacology and Therapeutics. 50(11). 838–850. 42 indexed citations

12.

Chapple, Christopher R., Jiří Klečka, Joanne Cummings, et al.. (2012). 683 Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB). European Urology Supplements. 11(1). e683–e683a. 11 indexed citations

13.

Drake, Marcus J., Mark Speakman, P. Van Kerrebroeck, Ted Drogendijk, & Monique Klaver. (2011). MP-05.01 Evaluating the Efficacy and Safety of Fixed-Dose Combinations of Tamsulosin OCAS™ and Solifenacin in Male LUTS with Storage and Voiding Symptoms: An Overview of the NEPTUNE Trial. Urology. 78(3). S58–S58. 2 indexed citations

14.

Cardozo, L., et al.. (2010). UP-2.35: Total urgency score (TUS) as a measure of frequency and urgency in SUNRISE. Urology. 76(3). S92–S92. 5 indexed citations

15.

Cardozo, Linda, Ted Drogendijk, & John Bolodeoku. (2008). The efficacy of solifenacin 5/10mg on ‘urgency’ endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study. 2 indexed citations

16.

Cardozo, Linda, Rodolfo Milani, Pedro Arañó, et al.. (2008). Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial. British Journal of Urology. 102(9). 1120–1127. 111 indexed citations

17.

Chapple, Christopher R., Ted Drogendijk, D.M. Wright, & John Bolodeoku. (2007). POS-01.134: Responses to solifenacin in patients >65 years and ≤65 years with overactive bladder syndrome: post-hoc results from the randomised, double-blind STAR study. Urology. 70(3). 232–232. 3 indexed citations

18.

Chapple, Christopher R., R. Martínez-García, Luigi Selvaggi, et al.. (2005). A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial. European Urology. 48(3). 464–470. 246 indexed citations

19.

Cardozo, L., R. J. Millard, Igor V. Kuzmin, et al.. (2004). RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER. The Journal of Urology. 172(5). 1919–1924. 250 indexed citations

20.

Cardozo, L., et al.. (2003). YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder. European Urology Supplements. 2(1). 28–28. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact